Abstract
Nursing and Residential CareVol. 16, No. 10 EditorialProstate cancer: considering the treatment optionsIan PeateIan PeateSearch for more papers by this authorIan PeatePublished Online:17 Sep 2014https://doi.org/10.12968/nrec.2014.16.10.548AboutSectionsView articleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareShare onFacebookTwitterLinked InEmail View article References Cancer Research UK (2014a) Prostate cancer incidence statistics. http://tinyurl.com/kxozyqh (accessed 21 August 2014) Google ScholarCancer Research UK (2014b) Prostate cancer statistics. http://tinyurl.com/ovphmtx (accessed 21 August 2014) Google ScholarCancer Research UK (2014c) Enzalutamide (Xtandi). http://tinyurl.com/lk2cxsn (accessed 21 August 2014) Google ScholarElectronic Medicines Compendium (2014) Enzalutamide. http://tinyurl.com/kl66xxl (accessed 21 August 2014) Google ScholarFeldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1): 34–45 Crossref, Google ScholarNational Institute for Health and Care Excellence (2014) NICE: Diagnosing and Treating Prostate Cancer. http://www.nice.org.uk/Guidance/CG175 (accessed 21 August 2014) Google ScholarNursing and Midwifery Council (2008) The Code: standards of conduct, performance and ethics for nurses and midwives. http://tinyurl.com/35om3cs (accessed 21 August 2014) Google ScholarProstate Cancer UK (2014) NICE's decision on enzalutamide means that some men will still miss out. http://tinyurl.com/kfn4pd6 (accessed 21 August 2014) Google ScholarScher HI, Fizazi K, Saad F et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13): 1187–97 Crossref, Google Scholar FiguresReferencesRelatedDetails 2 October 2014Volume 16Issue 10ISSN (print): 1465-9301ISSN (online): 2052-2932 Metrics History Published online 17 September 2014 Published in print 2 October 2014 Information© MA Healthcare LimitedPDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
